StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Phentermin

Phentermine

HCID 4771
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
122-09-8
Standard-SMILES
CC(C)(N)Cc1ccccc1
InChIKey
DHHVAGZRUROJKS-UHFFFAOYSA-N
Summenformel
C10H15N
Durchschnittliche Molmasse
149,23 g/mol
Monoisotopische Masse
149,12044948

Überblick

Benzeneethanamine, alpha,alpha-dimethyl- is an oily liquid. Insoluble in water.

Namen und Bezeichner

Bevorzugter Name
Phentermine
IUPAC
2-methyl-1-phenylpropan-2-amine
Lokaler Name
Phentermin
Englischer Name
PHENTERMINE
Summenformel
C10H15N
Molmasse
149.24

Namen und Synonyme

phentermineDuromineIonamin122-09-8LipopillMirapront2-methyl-1-phenylpropan-2-amineNormephentermineFenterminaLonaminOmnibexLinyl
Weitere Namen anzeigen
WilpoInoaminmg18570MG 18370
alpha,alpha-DimethylphenethylaminePhenterminumOberminePhentrol1,1-Dimethyl-2-phenylethylaminePhentrol 2Phentrol 3Phentrol 4

Datenbank-Bezeichner

CAS
122-09-8
PubChem CID
4771
DTXSID
DTXSID9023461
ChEMBL
CHEMBL1574
ChEBI
CHEBI:8080
UNII
C045TQL4WP
EC Number
204-522-1
Nikkaji
J5.348A

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1,9
Polarare Oberfläche (TPSA)
26 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
1
Frei drehbare Bindungen
2
Schwere Atome
11
Formalladung
0
Komplexität
112

Experimentelle und physikochemische Eigenschaften

Drugs · 5 Einträge

DEA NFLIS-Drug Category -> Phenethylamines (Amphetamines) (S)

DEA Schedule IV Controlled Substance -> Stimulants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP · 3 Einträge

log Kow = 1.90

2.2

1.9

OdorCHARACTERISTIC OF AMINES
Color/Form · 3 Einträge

Oily liquid

Colorless liquid

COLORLESS, MOBILE, OILY LIQUID

Solubility · 2 Einträge

SOL IN CHLOROFORM, ETHER, ACETONE & DIL ACIDS; SLIGHTLY SOL IN WATER

7.57e-01 g/L

Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Anti-Obesity Agents

Pharmaceuticals

Boiling Point205 °C at 750 mm Hg; 100 deg at 21 mm Hg

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 7% (3 of 43) of reports.

Danger

H301 (93%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 3 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory Information · 3 Einträge

DEA schedule IV controlled substance

REACH registered substance: Phentermine (EC: 204-522-1)

Phentermine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Benzeneethanamine, .alpha.,.alpha.-dimethyl-: Environment tier I assessment
DOT LabelPoison
Fire HazardsExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Health HazardsExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
FDA Requirements · 2 Einträge

Schedules of controlled substances are established by section 202 of the Controlled Substances Act (21 U.S.C. 812). Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers: Phentermine, Schedule IV, DEA Code #: 1640.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingThe protein binding of phentermine is determined to be of 17.5%.
Pharmacodynamics · 1 Eintrag

It is reported that the main mechanism of action of phentermine is the generation of appetite suppression, maybe due to the increase in leptin, but it is considered that other mechanisms should be involved. Some reports have indicated that the weight loss effect is mainly due to the increase in resting energy expenditure. In clinical studies where phentermine was used as a monotherapy and as combination therapy, this drug has shown an average weight loss of 3.6 kg when compared with the placebo in 2-24 weeks. Patients treated with phentermine also showed increased maintenance of the weight after treatment discontinuation. As well, even though it is a derivative of the amphetamines, it has not been registered to produce any of the effects of amphetamine such as central nervous system stimulation, elevation of blood pressure, tachyphylaxis or QTc prolongation.

Mechanism of Action · 2 Einträge

Phentermine is an indirect-acting sympathomimetic agent that acts by releasing noradrenaline from the presynaptic vesicles in the lateral hypothalamus. This increase in noradrenaline concentration in the synaptic cleft results in the stimulation of beta2-adrenergic receptors. Phentermine is classified as an indirect sympathomimetic due to the increase in the level of norepinephrine, dopamine and its indirect effect towards serotonin. Some reports have indicated that phentermine inhibits the neuropeptide Y which is a principal signaling pathway for the induction of hunger. This combined effect produces a continuous flight-or-fight response in the body which reduces the hunger signal as this state is on the immediate need for energy. Lastly, some reports have indicated that phentermine is a weak inhibitor of monoamine oxidase but this mechanism does not tend to produce a clinically significant response.

Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications ... are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. ... It has not been established that the actions of these medications in treating obesity is primarily suppression of appetite; other CNS actions and/or metabolic effects, such as decreased gastric acid secretion or increased energy expenditure, may be involved.

Zugehörige Reaktionen

22
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 295004
HRID 295004als Edukt
Reaktionsgleichung von HRID 819250
HRID 819250als Edukt
Reaktionsgleichung von HRID 843036
HRID 843036als Edukt
Reaktionsgleichung von HRID 862292
HRID 862292als Edukt
Reaktionsgleichung von HRID 961586
HRID 961586als Edukt
Reaktionsgleichung von HRID 962690
HRID 962690als Edukt
Reaktionsgleichung von HRID 990762
HRID 990762als Edukt
Reaktionsgleichung von HRID 991771
HRID 991771als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Melting Point · 2 Einträge

Crystals. MP: 198 °C /Hydrochloride/

205 °C

Physical Description · 2 Einträge

Benzeneethanamine, alpha,alpha-dimethyl- is an oily liquid. Insoluble in water.

Solid

Dissociation Constants9.84
Other Experimental Properties · 2 Einträge

Odorless or has faint characteristic odor; white, crystalline powder; very soluble in chloroform; insoluble in ether; very slightly soluble in benzene & acetone. /Phentermine hydrochloride/

White, odorless, hygroscopic, crystalline powder; soluble in water and lower alcohols, slightly soluble in chloroform, and insoluble in ether. /Hydrochloride/

Physikochemische Eigenschaften

Schmelzpunkt
143 °C · 143°C (estimate)
Siedepunkt
750 · bp750 205°; bp21 100°
Dichte
0 · 0,93 g/cm3
Dampfdruck
32.4 Pa · 32.4Pa at 25℃
Brechungsindex
1.509 · 1.5090 (estimate)
Flammpunkt
100 °C · 100 °C
storage temp.
0 · Store at 0-5°C
Löslichkeit
50 mg/ml · Methanol: 50 mg/ml
Aggregatzustand
Oil
pka
10.11 · pKa 10.11 (Uncertain)
Farbe
Colourless to Pale Yellow
Wasserlöslichkeit
18.6 g/L · 18.6g/L at 25℃
Henry's Law Constant
7 · 7.0×100 mol/(m3Pa) at 25℃, HSDB (2015)
LogP
1.9 at · 1.9 at 25℃
EPA chemische Informationen
.alpha.,.alpha.-Dimethylphenethylamine (122-09-8)

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl phentermine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Phentermine Hydrochloride/

Reactive GroupAmines, Phosphines, and Pyridines
RCRA Requirements · 1 Eintrag

P046; As stipulated in 40 CFR 261.33, when alpha,alpha-dimethylphenethylamine as a commercial chemical product or manufacturing chemical intermediate or an off-specification commercial chemical product or a manufacturing chemical intermediate, becomes a waste, it must be managed according to federal and/or state hazardous waste regulations. Also defined as a hazardous waste is any container or inner liner used to hold this waste or any residue, contaminated soil, water, or other debris resulting from the cleanup of a spill, into water or on dry land, of this waste. Generators of small quantities of this waste may qualify for partial exclusion from hazardous waste regulations (40 CFR 261.5(e)).

TSCA Requirements · 1 Eintrag

Pursuant to section 8(d) of TSCA, EPA promulgated a model Health and Safety Data Reporting Rule. The section 8(d) model rule requires manufacturers, importers, and processors of listed chemical substances and mixtures to submit to EPA copies and lists of unpublished health and safety studies. Benzeneethanamine, alpha,alpha-dimethyl- is included on this list.

Reactivity Profile · 1 Eintrag

BENZENEETHANAMINE, ALPHA,ALPHA-DIMETHYL- neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. May generate hydrogen, a flammable gas, in combination with strong reducing agents such as hydrides.

Air and Water ReactionsInsoluble in water.
EPA Hazardous Waste NumberP046; An acute hazardous waste when a discarded commercial chemical product or manufacturing chemical intermediate or an off-specification commercial chemical product or a manufacturing chemical intermediate.

Sicherheit und Schutzausrüstung

Fire FightingExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
First AidExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Storage Conditions · 1 Eintrag

Phentermine hydrochloride capsules and tablets should be stored in tight and well-closed containers, respectively, at a temperature less than 40 °C, preferably at 15-30 °C. Capsules containing phentermine as a resin complex should be stored in tight containers at 15-30 °C. . /Phentermine hydrochloride/

Nonfire Spill ResponseExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Disposal Methods · 2 Einträge

Generators of waste (equal to or greater than 100 kg/mo) containing this contaminant, EPA hazardous waste number P046, must conform with USEPA regulations in storage, transportation, treatment and disposal of waste.

A good candidate for liquid injection incineration at a temperature range of 650 to 1,600 °C and a residence time of 0.1 to 2 seconds. A good candidate for rotary kiln incineration at a temperature range of 820 to 1,600 °C and residence times of seconds for liquids and gases, and hours for solids. A good candidate for fluidized bed incineration at a temperature range of 450 to 980 °C and residence times of seconds for liquids and gases, and longer for solids.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE)Excerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:

Toxikologische Informationen

Treatment · 1 Eintrag

Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (REGITINE) has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage. (L1712)

Interactions · 5 Einträge

'Fen-phen' refers to the off-label combination of the appetite suppressants fenfluramine and phentermine. The rationale for the fen-phen combination was that the two drugs exerted independent actions on brain satiety mechanisms so that it was possible to use lower doses of each drug and yet retain a common action on suppressing appetite while minimizing adverse drug effects. The focus of the present review is to consider whether fenfluramine and phentermine exert actions that are additive in nature or whether these two drugs exhibit drug-drug synergism. The fen-phen combination results in synergism for the suppression of appetite and body weight, the reduction of brain serotonin levels, pulmonary vasoconstriction and valve disease. Fen-phen synergism may reflect changes in the pharmacokinetics of drug distribution, common actions on membrane ion currents, or interactions between neuronal release and reuptake mechanisms with MAO-mediated transmitter degradation. The synergism between fenfluramine and phentermine highlights the need to more completely understand the pharmacology and neurochemistry of appetite suppressants prior to use in combination pharmacotherapy for the treatment of obesity.

An increased prevalence of abnormal cardiac valve function, primarily aortic regurgitation, was found on echocardiographic evaluation in patients receiving phentermine in combination with either dexfenfluramine or fenfluramine, both of which act to suppress appetite by increasing serotonergic function; however, an increased prevalence of abnormal cardiac valve function also has been found in patients receiving dexfenfluramine or fenfluramine alone, and the role of phentermine in producing the cardiotoxic effect is uncertain; because of the severity of these cardiovascular effects and because the safety and efficacy of other appetite suppressant combinations have not been established, combined use is not recommended; also, the safety and efficacy of combining as selective serotonin reuptake inhibitor (SSRI), which enhances serotonergic function, with a sympathomimetic appetite suppressant have not been established and combined use is not recommended.

Concurrent use /of other CNS stimulation-producing medications or thyroid hormones with appetite suppressants/ may increase the CNS stimulant effects of either these medications or the appetite suppressant. /Appetite suppressants, sympathomimetic/

Vasopressant effect may be potentiated; if necessary to administer a pressor amine agent to a patient who has recently received an appetite suppressant, initiating pressor therapy in reduced dosage and monitoring blood pressure at frequent intervals are recommended. /Appetite suppressants, sympathomimetic/

For more Interactions (Complete) data for PHENTERMINE (11 total), please visit the HSDB record page.

Health Effects · 1 Eintrag

Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.

Hepatotoxicity · 1 Eintrag

Phentermine has not been linked to an increased rate of serum enzyme elevations during therapy; however, results of ALT monitoring during phentermine therapy have rarely been reported. Despite long term availability and wide use of phentermine, there have been no published reports linking it to clinically apparent acute liver injury.

Environmental Fate · 3 Einträge

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 260(SRC), determined from a log Kow of 1.90(2) and a regression-derived equation(3), indicates that phentermine is expected to have moderate mobility in soil(SRC). The estimated pKa of phentermine is 10.1(4), indicating that this compound will primarily exist in the cation form in the environment and cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(5). Volatilization of phentermine from moist soil surfaces is expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.4X10-6 atm-cu m/mole(SRC), using a fragment constant estimation method(6). Phentermine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 9.6X10-2 mm Hg(SRC), determined from a fragment constant method(7). Biodegradation data were not available(SRC, 2005).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 260(SRC), determined from a log Kow of 1.90(2) and a regression-derived equation(3), indicates that phentermine is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 10.1(4) indicates phentermine will exist primarily in the cation form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process(5). Volatilization from water surfaces is expected(3) based upon an estimated Henry's Law constant of 1.4X10-6 atm-cu m/mole(SRC), developed using a fragment constant estimation method(6). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 31 and 232 days, respectively(SRC). According to a classification scheme(7), an estimated BCF of 6(SRC), from its log Kow(2) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2005).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), phentermine, which has an estimated vapor pressure of 9.6X10-2 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely as a vapor in the ambient atmosphere. Vapor-phase phentermine is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 14 hours(SRC), calculated from its rate constant of 2.7X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Phentermine does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Exposure RoutesPhentermine is rapidly absorbed after oral ingestion.
Toxicity Summary · 2 Einträge

IDENTIFICATION: Phentermine hydrochloride is an amphetamine type antiobesity drug. Description: Indications: Used as an appetite suppressant (anorectic). Misuse: Performance enhancement and relief of fatigue. Abuse: Abuse either orally or by injection is extremely common. HUMAN EXPOSURE: Main risks and target organs: Acute central nervous system stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Summary of clinical effects: Cardiovascular: Palpitation, chest pain, tachycardia, arrhythmias and hypertension are common; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. Central Nervous System (CNS): Stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia are described. Stroke and cerebral vasculitis have been observed. Gastrointestinal: Vomiting, diarrhea and cramps may occur. Acute transient ischemic colitis has occurred with chronic abuse. Genitourinary: Increased bladder sphincter tone may cause dysuria, hesitancy and acute urinary retention. Renal failure can result secondary to dehydration or rhabdomyolysis. Renal ischemia may be noted. Dermatologic: Skin is usually pale and diaphoretic, but mucous membranes appear dry. Endocrine: Transient hyperthyroxinemia may be noted. Metabolism: Increased metabolic and muscular activity may result in hyperventilation and hyperthermia. Weight loss is common with chronic use. Fluid/Electrolyte: Hypo- and hyperkalemia have been reported. Dehydration is common. Musculoskeletal: Fasciculations and rigidity may be noted. Rhabdomyolysis is an important consequence of severe poisoning. Psychiatric: Agitation, confusion, mood elevation, increased wakefulness, talkativeness, irritability and panic attacks are typical. Chronic abuse can cause delusions and paranoia. A withdrawal syndrome occurs after abrupt cessation following chronic use. Contraindications: Anorexia, insomnia, psychopathic personality disorders, suicidal tendencies, Tourette syndrome and other disorders, hyperthyroidism, narrow angle glaucoma, diabetes mellitis and cardiovascular diseases such as angina, hypertension and arrhythmias. Interacts with several other drugs. Routes of exposure: Oral: Readily absorbed from the gastro-intestinal tract and buccal mucosa. It is resistant to metabolism by monoamine oxidase. Inhalation: Rapidly absorbed by inhalation and is abused by this route. Parenteral: Frequent route of entry in abuse situations. Absorption by route of exposure: Rapidly absorbed after oral ingestion. Peak plasma levels occur within 1 to 3 hours, varying with the degree of physical activity and the amount of food in the stomach. Absorption is usually complete by 4 to 6 hours. Sustained release preparations are available as resin-bound, rather than soluble, salts. These compounds display reduced peak blood levels compared with standard preparations, but total amount absorbed and time to peak levels remain similar. Distribution by route of exposure: Concentrated in the kidney, lungs, cerebrospinal fluid and brain. They are highly lipid soluble and readily cross the blood-brain barrier. Protein binding and volume of distribution varies widely. Biological half-life by route of exposure: Under normal conditions, about 30% is excreted unchanged in the urine but this excretion is highly variable and is dependent on urinary pH. When the urinary pH is acidic (pH 5.5 to 6.0), elimination is predominantly by urinary excretion with approximately 60% of a dose of being excreted unchanged by the kidney within 48 hours. When the urinary pH is alkaline (pH 7.5 to 8.0), elimination is predominantly by deamination (less than 7% excreted unchanged in the urine); the half-life ranging from 16 to 31 hours. Metabolism: The major metabolic pathway involves deamination by cytochrome P450 to para-hydroxyamphetamine and phenylacetone; this latter compound is subsequently oxidized to benzoic acid and excreted as glucuronide or glycine (hippuric acid) conjugate. Smaller amounts are converted to norephedrine by oxidation. Hydroxylation produces an active metabolite, O-hyroxynorephedrine, which acts as a false neurotransmitter and may account for some drug effect, especially in chronic users. Elimination and excretion: Normally 5 to 30% of a therapeutic dose is excreted unchanged in the urine by 24 hours, but the actual amount of urinary excretion and metabolism is highly pH dependent. Human data: Adults: The toxic dose varies considerably due to individual variations and the development of tolerance. Children: Children appear to be more susceptible than adults and are less likely to have developed tolerance. Teratogenicity: Mild withdrawal symptoms may be observed in the newborn, but the few studies of infant follow-up have not shown long term sequelae, although more studies of this nature are needed. Illicit maternal use or abuse presents a significant risk to the fetus and newborn, including intrauterine growth retardation, premature delivery and the potential for increased maternal, fetal and neonatal morbidity. These poor outcomes are probably multifactorial in origin, involving multiple drug use, life-styles and poor maternal health. However, cerebral injuries occurring in newborns exposed in utero appear to be directly related to the vasoconstrictive properties. Intelligence, psychological function, growth, and physical health were all within the normal range at eight years, but those children exposed throughout pregnancy tended to be more aggressive. Interactions: Acetazolamide: administration may increase serum concentration. Alcohol: may increase serum concentration. Ascorbic acid: lowering urinary pH, may enhance excretion. Furazolidone: May induce a hypertensive response in patients taking furazolidone. Guanethidine: This drug inhibits the antihypertensive response to guanethidine. Haloperidol: limited evidence indicates that haloperidol may inhibit the effects but the clinical importance of this interaction is not established. Lithium carbonate: isolated case reports indicate that lithium may inhibit the effects. Monoamine oxidase inhibitor: severe hypertensive reactions have followed the administration to patients taking monoamine oxidase inhibitors. Noradrenaline: Abuse may enhance the pressor response to noradrenaline. Phenothiazines: May inhibit the antipsychotic effect of phenothiazines, and phenothiazines may inhibit the anorectic effect. Sodium bicarbonate: large doses of sodium bicarbonate inhibit the elimination, thus increasing the effect. Tricyclic antidepressants: theoretically increases the effect, but clinical evidence is lacking. Clinical effects: Acute poisoning:Ingestion: Effects are most marked on the central nervous system, cardiovascular system, and muscles. The triad of hyperactivity, hyperpyrexia, and hypertension is characteristic of acute overdosage. Agitation, confusion, headache, delirium, and hallucination, can be followed by coma, intracranial hemorrhage, stroke, and death. Chest pain, palpitation, hypertension, tachycardia, atrial and ventricular arrhythmia, and myocardial infarction can occur. Muscle contraction, bruxism (jaw-grinding), trismus (jaw clenching), fasciculation, rhabdomyolysis, are seen leading to renal failure; and flushing, sweating, and hyperpyrexia can all occur. Hyperpyrexia can cause disseminated intravascular coagulation. Inhalation: The clinical effects are similar to those after ingestion, but occur more rapidly. Parenteral exposure: Intravenous injection is a common mode of administration by abusers. The euphoria produced is more intense, leading to a rush or flash which is compared to sexual orgasm. Other clinical effects are similar to those observed after ingestion, but occur more rapidly. Chronic poisoning: Ingestion: Tolerance to the euphoric effects and CNS stimulation induced develops rapidly, leading abusers to use larger and larger amounts to attain and sustain the desired affect. Habitual use or chronic abuse usually results in toxic psychosis classically characterized by paranoia, delusions and hallucinations, which are usually visual, tactile or olfactory in nature, in contrast to the typical auditory hallucinations of schizophrenia. The individual may act on the delusions, resulting in bizarre violent behavior, hostility and aggression, sometimes leading to suicidal or homicidal actions. Dyskinesia, compulsive behavior and impaired performance are common in chronic abusers. The chronic abuser presents as a restless, garrulous, tremulous individual who is suspicious and anxious. Course, prognosis, cause of death: Symptoms and signs give a clinical guide to the severity of intoxication as follows: Mild toxicity: restlessness, irritability, insomnia, tremor, hyperreflexia, sweating, dilated pupils, flushing; Moderate toxicity: hyperactivity, confusion, hypertension, tachypnea, tachycardia, mild fever, sweating; Severe toxicity: delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, circulatory collapse. Death can be due to intracranial hemorrhage, acute heart failure or arrhythmia, hyperpyrexia, rhabdomyolysis and consequent hyperkalemia or renal failure, and to violence related to the psychiatric effects. Systematic description of clinical effects: Cardiovascular: Cardiovascular symptoms of acute poisoning include palpitation and chest pain. Tachycardia and hypertension are common. One third of patients reported had a blood pressure greater than 140/90 mmHg, and nearly two-thirds had a pulse rate above 100 beats per minute. Severe poisoning can cause acute myocardial ischemia, myocardial infarction, and left ventricular failure. These probably result from vasospasm, perhaps at sites of existing atherosclerosis. In at least one case, thrombus was demonstrated initially. Chronic oral amphetamine abuse can cause a chronic cardiomyopathy; an acute cardiomyopathy has also been described. Hypertensive stroke is a well-recognized complication of poisoning. Intra-arterial injection can cause severe burning pain, vasospasm and gangrene. Respiratory: Pulmonary fibrosis, right ventricular hypertrophy and pulmonary hypertension are frequently found at post-mortem examination. Pulmonary function tests usually are normal except for the carbon monoxide diffusing capacity. Respiratory complications are sometimes caused by fillers or adulterants used in injections by chronic users. These can cause multiple microemboli to the lung, which can lead to restrictive lung disease. Pneumomediastinum has been reported after inhalation. Neurological: Central nervous system (CNS): Main symptoms include agitation, confusion, delirium, hallucinations, dizziness, dyskinesia, hyperactivity, muscle fasciculation and rigidity, rigors, tics, tremors, seizures and coma. Both occlusive and hemorrhagic strokes have been reported after abuse.. Twenty-one of 73 drug-using young persons with stroke had taken amphetamine. A study found six individuals had documented intracerebral hemorrhage and two had subarachnoid hemorrhage. Patients with underlying arteriovenous malformations may be at particular risk. Stroke can occur after oral, intravenous, or nasal administration. Severe headache beginning within minutes of ingestion is usually the first symptom. In more than half the cases, hypertension which is sometimes extreme, accompanies other symptoms. A Cerebral vasculitis has also been observed. Dystonia and dyskinesia can occur, even with therapeutic dosages. Psychiatric effects, particularly euphoria and excitement, are the motives for abuse. Paranoia and a psychiatric syndrome indistinguishable from schizophrenia are sequelae of chronic use. Autonomic nervous system: Stimulation of alpha-adrenergic receptors produces mydriasis, increased metabolic rate, diaphoresis, increased sphincter tone, peripheral vasoconstriction and decreased gastrointestinal motility. Stimulation of ß-adrenergic receptors produces increased heart rate and contractility, increased automaticity and dilatation of bronchioles. Gastrointestinal: Most common symptoms are nausea, vomiting, diarrhea, and abdominal cramps. Anorexia may be severe. Epigastric pain and hematemesis have been described after intravenous use. A case of ischemic colitis with normal mesenteric arteriography in a patient taking dexamphetamine has been described. Hepatic: Hepatitis and fatal acute hepatic necrosis have been described. Urinary: Renal: Renal failure, secondary to dehydration or rhabdomyolysis may be observed. Other: Increased bladder sphincter tone may cause dysuria, hesitancy and acute urinary retention. This effect may be a direct result of peripheral alpha-agonist activity. Spontaneous rupture of the bladder has been described in a young woman who took alcohol and an amphetamine-containing diet tablet. Endocrine and reproductive systems: Transient hyperthyroxinemia may result from heavy use. Dermatological: Skin is usually pale and diaphoretic, but mucous membranes appear dry. Chronic users may display skin lesion, abscesses, ulcers, cellulitis or necrotizing angiitis due to physical insult to skin, or dermatologic signs of dietary deficiencies such as cheilosis and purpura. Eye, ear, nose, throat: local effects: Mydriasis may be noted. Diffuse hair loss may be noted. Chronic users may display signs of dietary deficiencies. Hematological: Disseminated intravascular coagulation is an important consequence of severe poisoning. Idiopathic thrombocytopenic purpura may occur. Fluid and electrolyte disturbance: Increase metabolic and muscular activity may result in dehydration. Special risks: Pregnancy: Intelligence, psychological function, growth, and physical health were all within the normal range at eight years, but those exposed throughout pregnancy tended to be more aggressive. A case report describes a normal female infant born to mother who took dexamphetamine for narcolepsy throughout pregnancy. Breast-feeding: Amphetamine is passed into breast milk and measurable amounts can be detected in breast-fed infant's urine. Therefore lactating mothers are advised not to take or use these drugs. /Phentermine hydrochloride/

Signs and SymptomsSymptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.
Effluent ConcentrationsPhentermine was tested for but not detected (detection limit = 1.0 ug/L) in leachate water samples following the addition to 29 tire plugs (10.25 cm diameter) to 16 liters of Lake Mead, Nevada water for a period of 31 days(1).
Soil Adsorption/Mobility · 1 Eintrag

The Koc of phentermine is estimated as 260(SRC), using a log Kow of 1.90(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that phentermine is expected to have moderate mobility in soil(SRC). The estimated pKa of phentermine is 10.1(4), indicating that this compound will primarily exist in the cation form in the environment and cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(5).

Human Toxicity Excerpts · 5 Einträge

/CASE REPORTS/ A 47-year-old mildly obese female began a weight reduction program that included anorectic therapy with phentermine and phendimetrazine. A normal urinalysis and serum creatinine were documented at the start of therapy. After three weeks of treatment, the patient felt ill and discontinued her treatment. Subsequently she was found to have leukocyturia, a rash on her face and chest, and a rise in her serum creatinine from 0.8 mg/dl to 2.1 mg/dl. A renal biopsy confirmed the diagnosis of acute interstitial nephritis. The patient was treated with corticosteroids and her renal function returned to normal. Despite the recent withdrawal of two anorectic agents due to data linking them to severe cardiac and pulmonary disease, the appetite suppressants phentermine and phendimetrazine remain in widespread usage for the treatment of obesity. This case represents the first report of acute interstitial nephritis associated with phentermine or phendimetrazine.

/CASE REPORTS/ Psychotic reactions that could easily be mistaken for schizophrenic illness were reported in 20 yr old woman who had been taking phentermine (ionamin), 30 mg/day for 3 mo, beginning 1 mo prior to onset of symptoms.

/CASE REPORTS/ Acutely intoxicated patients exhibit tremor, hyperreflexia, rapid respiration, confusion, assaultive behavior, hallucinations, panic, nausea, vomiting, diarrhea and abdominal cramps. Death may occur following convulsions and coma. A 26-year-old schizophrenic woman developed an acute psychotic disorganization with mydriasis, tachycardia and restlessness after 240 mg, /of/ phentermine. ... Signs of chronic intoxication are severe dermatoses, marked insomnia, irritability, hyperactivity and, in the severe cases, a psychosis resembling schizophrenia. Extreme fatigue, mental depression and changes in the sleep EEG have been observed after abrupt cessation of long-term usage.

/EPIDEMIOLOGY STUDIES/ ...A population-based follow-up study and a nested case-control analysis of 6532 subjects who received dexfenfluramine, 2371 who received fenfluramine, and 862 who received phentermine /was conducted/ to assess the risk of a subsequent clinical diagnosis of a valvular disorder of uncertain origin. For comparison, a group of 9281 obese subjects who had not taken appetite suppressants were matched to the treated subjects for age, sex, and weight. All subjects were free of diagnosed cardiovascular disease at the start of follow-up. The average duration of follow-up for all subjects was about four years. There were 11 cases of newly diagnosed idiopathic valvular disorders, 5 after the use of dexfenfluramine and 6 after the use of fenfluramine. There were six cases of aortic regurgitation, two cases of mitral regurgitation, and three cases of combined aortic and mitral regurgitation. There were no cases of idiopathic cardiac-valve abnormalities among the subjects who had not taken appetite suppressants or among those who took only phentermine. The five-year cumulative incidence of idiopathic cardiac-valve disorders was 0 per 10,000 subjects among those who had not taken appetite suppressants (95 percent confidence interval, 0 to 15.4) and among those who took phentermine alone (95 percent confidence interval, 0 to 76.6), 7.1 per 10,000 subjects among those who took either fenfluramine or dexfenfluramine for less than four months (95 percent confidence interval, 3.6 to 17.8; P=0.02 for the comparison with subjects who had not taken appetite suppressants), and 35.0 per 10,000 subjects among those who received either of these medications for four or more months (95 percent confidence interval, 16.4 to 76.2; P<0.001). The use of fenfluramine or dexfenfluramine, particularly for four months or longer, is associated with an increased risk of newly diagnosed cardiac-valve disorders, particularly aortic regurgitation.

Artificial Pollution Sources · 1 Eintrag

Phentermine's production and use as an appetite suppressant(1) may result in its release to the environment through various waste streams(SRC). It was a component of the popular diet-drug combination of fenfluramine and phnetermine (Fen/phen)(1).

Regulatorische Informationen

FDA Requirements · 2 Einträge

Schedules of controlled substances are established by section 202 of the Controlled Substances Act (21 U.S.C. 812). Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers: Phentermine, Schedule IV, DEA Code #: 1640.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl phentermine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Phentermine Hydrochloride/

RCRA Requirements · 1 Eintrag

P046; As stipulated in 40 CFR 261.33, when alpha,alpha-dimethylphenethylamine as a commercial chemical product or manufacturing chemical intermediate or an off-specification commercial chemical product or a manufacturing chemical intermediate, becomes a waste, it must be managed according to federal and/or state hazardous waste regulations. Also defined as a hazardous waste is any container or inner liner used to hold this waste or any residue, contaminated soil, water, or other debris resulting from the cleanup of a spill, into water or on dry land, of this waste. Generators of small quantities of this waste may qualify for partial exclusion from hazardous waste regulations (40 CFR 261.5(e)).

TSCA Requirements · 1 Eintrag

Pursuant to section 8(d) of TSCA, EPA promulgated a model Health and Safety Data Reporting Rule. The section 8(d) model rule requires manufacturers, importers, and processors of listed chemical substances and mixtures to submit to EPA copies and lists of unpublished health and safety studies. Benzeneethanamine, alpha,alpha-dimethyl- is included on this list.

CERCLA Reportable Quantities · 1 Eintrag

Persons in charge of vessels or facilities are required to notify the National Response Center (NRC) immediately, when there is a release of this designated hazardous substance, in an amount equal to or greater than its reportable quantity of 5000 lb or 2270 kg. The toll free number of the NRC is (800) 424-8802. The rule for determining when notification is required is stated in 40 CFR 302.4 (section IV. D.3.b).

Sicherheitsdaten

wgk
1
tsca
TSCA listed
ridadr
1851
risk_code
20/21/22-36/37/38-40-39/23/24/25-23/24/25-11-67
Toxizität
man,TDLo,oral,1429ug/kg (1.429mg/kg),AUTONOMIC NERVOUS SYSTEM: SYMPATHOMIMETIC,Therapie. Vol. 34, Pg. 205, 1979.
hazard_code
Xn,T,F
safety_code
26-36/37/39-36/37-24/25-23-45-16
hazard_class
6.1(b)
packing_group
III
Giftige Stoffe Daten
122-09-8(Hazardous Substances Data)
Biological Half-Life · 3 Einträge

The mean terminal half-life of phentermine is reported to be of approximately 20 hours. In conditions where there is acidic urine (pH <5), the elimination half-life is of 7-8 hours.

... Elimination half-life is approximately 7-8 hours in acid urine (pH5), compared with 19-24 hours under normal conditions.

S(+)-phentermine was eliminated much more rapidly in rat (k= 1.32/hr) after iv administration than in man (k= 0.029/hr) after oral dose. Half-lives were 25-35 min in rat & 12-24 hr in man.

Metabolism/Metabolites · 6 Einträge

Phentermine undergoes minimal p-hydroxylation, N-oxidation and N-hydroxylation followed by conjugation. The total proportion of the drug that goes under metabolism only represents about 6% of the administered dose where about 5% is represented by the N-oxidized and N-Hydroxylated metabolites.

Phentermine is not significantly biotransformed; 70 to 80 % of a given dose is excreted unchanged in the urine.

There are two primary pathways of oxidative metabolism: n-hydroxylation to n-hydroxyphentermine & p-hydroxylation to para-hydroxyphentermine. N-hydroxyphentermine is metabolized further to alpha-nitrophentermine. In rats the dominant pathway is p-hydroxylation to give para-hydroxyphentermine, accounting for more than 60% of administered dose. P-hydroxylation reactions in rat liver microsomes indicated that phentermine metabolism was inhibited by skf525a & iprindol, and was not inducible with phenobarbital or 3-methylcholanthrene, suggesting a system different from aromatic c-hydroxylation. The n-hydroxylation reaction for rabbit & guinea pig (two-enzyme system) & rat (single enzyme system) is the reduced form of nicotinamide-adenine dinucleotide phosphate-dependent, inhibited by carbon monoxide & induced by phenobarbital, suggesting involvement of cytochrome p450 system.

Although no quantitative data are available, urinary metabolites found in man are p-hydroxyphentermine and n-hydroxyphentermine. N-hydroxy metabolite can be reduced in vivo but conversion to this metabolite appears to be inefficient means of elimination.

The role of the cytochrome p450 system in the oxidation of phentermine to N-hydroxyphentermine by liver microsomal prepn was studied in a reconstituted system which consisted of cytochrome p450 and the reduced form of nicotinamide-adenine dinucleotide phosphate cytochrome p450 reductase purified from liver microsomes of phenobarbital-induced rabbits. In this system, phentermine was oxidized to N-hydroxyphentermine. The reaction was the reduced form of nicotinamide-adenine dinucleotide phosphate-dependent and required the presence of both the cytochrome p450 and reductase preparations.

Hepatic. Half Life: 16 to 31 hours

FDA Pharmacological Classification · 6 Einträge

C045TQL4WP

PHENTERMINE

Physiologic Effects [PE] - Appetite Suppression

Physiologic Effects [PE] - Increased Sympathetic Activity

Established Pharmacologic Class [EPC] - Sympathomimetic Amine Anorectic

Phentermine is a Sympathomimetic Amine Anorectic. The physiologic effect of phentermine is by means of Appetite Suppression and Increased Sympathetic Activity.

MeSH Pharmacological Classification · 4 Einträge

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Agents that are used to suppress appetite.

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Absorption, Distribution and Excretion · 6 Einträge

Phentermine shows a dose-dependent pharmacokinetic profile. After oral administration of a dose of 15 mg, the maximal concentration was achieved after 6 hours and its bioavailability was not affected by the consumption of high-fat meals. The reported plasma concentration at steady-state is of around 200 ng/ml as observed in clinical trials.

Phentermine is excreted mainly in the urine from which about 70-80% of the administered dose can be found as the unchanged drug.

The reported volume of distribution for phentermine is reported to be of 5 L/kg.

The reported clearance when administered orally is 8.79 L/h as observed in pharmacokinetic population studies.

Absorbed readily after oral administration. Distributed widely throughout body.

The volume of distribution is 3 to 4 L/kg ... A majority of the drug is excreted unchanged in the urine. An average of 48% of the dose is excreted in the urine in 24 hours, which increases to 84% in acidic urine.

Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 5 Einträge

Appetite suppressant for the short-term (a few weeks) management of obesity

THERAP CAT: Anorectic agent

MEDICATION

Use (kg) in USA (2002): 4170

For the treatment and management of obesity.

Methods of Manufacturing · 4 Einträge

Preperation: Shelton, Van Campen, US 2590079 (1952 to Wyeth)

Prepartion: ... Abell et al., US 2408345 (1946 to Wm. S. Merrell)

Grignardization of benzyl alcohol with acetone, reacting the resulting alpha, alpha-dimethylpenethyl alcohol with sodium cyanide in acid to form the corresponding 2-formamido compound, and hydrolyzing this to phentermine.

Phentermine is prepared by converting the condensation product of benzaldehyde and nitropropane to the corresponding aminoalcohol followed by transformation to the chloroamine and then catalytic hydrogenation.

Formulations/Preparations · 5 Einträge

ADIPEX-P, FASTIN, WILPO. /PHENTERMINE HYDROCHLORIDE/

/INGREDIENT OF/ IONAMIN, MIRAPRONT, LINYL, OMNIBEX, DUROMINE /ION EXCHANGE RESIN COMPLEX/

PHENTERMINE IS AVAIL AS HYDROCHLORIDE SALT & AS COMPLEX OF BASE WITH AN ION-EXCHANGE RESIN. ... GENERIC: CAPSULES 15, 18, 75, 30, AND 37.5 MG; TABLETS 8, 30, AND 37.5 MG. ADIPEX-P (LEMMON): CAPSULES AND TABLETS 37.5 MG (EQUIVALENT TO 30 MG OF BASE). FASTIN (BEECHAM), OBERMINE (FOREST): CAPSULES 30 MG (EQUIVALENT TO 24 MG OF BASE). PHENTROL (VORTECH): CAPSULES 30 MG (EQUIVALENT TO 24 MG OF BSE) (PHENTROL 2); CAPSULES (PROLONGED-RELEASE) 15 MG (EQUIVALENT TO 12 MG OF BASE) (PHENTROL 3) AND 30 MG (EQUIVALENT TO 24 MG OF BASE) (PHENTROL 4); TABLETS 8 MG (EQUIVALENT TO 6.4 MG OF BASE) (PHENTROL) PHENTERMINE RESIN: IONAMIN (FISONS), GENERIC. ORAL: CAPSULES 15 AND 30 MG.

Each tablet /of Adipex-P/ contain phentermine hydrochloride, 37.5 mg (equivalent to 30 mg of phentermine base)

For more Formulations/Preparations (Complete) data for PHENTERMINE (6 total), please visit the HSDB record page.

Use ClassificationPharmaceuticals
General Manufacturing Information · 5 Einträge

Benzeneethanamine, .alpha.,.alpha.-dimethyl-: ACTIVE

Phentermine is a chemical congener of amphetamine in that it has an additional methyl group on alpha-carbon atom, which is symmetrical & lacks an alpha-hydrogen atom. These differences from amphetamine are reflected in metabolism & pharmacology.

An anorectic drug supplied as a cationic resin complex ... and as the hydrochloride salt.

... has not been marketed in the Federal Republic of Germany since 1968 because of suspected pulmonary hypertension

Fen-phen refers to the off-label combination of the appetite suppressants fenfluramine and phentermine

Anwendungen

VerwendenAppetite suppressant (systemic).

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

HydrogenchloridNatriumAmmoniak, wasserfreiIsobutyrylchloridα-BromtoluolBenzolCalciumdihydroxidKaliumhydroxidAcetamide,2-chloro-N-(1,1-dimethyl-2-phenylethyl)-2-methyl-2-nitro-1-phenylpropane4-(2-amino-2-methylpropyl)benzenamine2-Amino-2-methyl-1-phenyl-propan-1-olN-hydroxyphentermineN-(1,1-DiMethyl-2-phenylethyl)acetaMidN-(α,α-Dimethylphenethyl)formamidBenzylmagnesiumchlorid

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.

For more Human Toxicity Excerpts (Complete) data for PHENTERMINE (6 total), please visit the HSDB record page.